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Abstract
Context: Establishing the long-term benefit of therapy in chronic diseases has been challenging. Long-term studies require
non-randomized designs and, thus, are often confounded by biases. For example, although disease-modifying therapy in
MS has a convincing benefit on several short-term outcome-measures in randomized trials, its impact on long-term function
remains uncertain.
Objective: Data from the 16-year Long-Term Follow-up study of interferon-beta-1b is used to assess the relationship
between drug-exposure and long-term disability in MS patients.
Design/Setting: To mitigate the bias of outcome-dependent exposure variation in non-randomized long-term studies,
drug-exposure was measured as the medication-possession-ratio, adjusted up or down according to multiple different
weighting-schemes based on MS severity and MS duration at treatment initiation. A recursive-partitioning algorithm
assessed whether exposure (using any weighing scheme) affected long-term outcome. The optimal cut-point that was used
to define ‘‘high’’ or ‘‘low’’ exposure-groups was chosen by the algorithm. Subsequent to verification of an exposure-impact
that included all predictor variables, the two groups were compared using a weighted propensity-stratified analysis in order
to mitigate any treatment-selection bias that may have been present. Finally, multiple sensitivity-analyses were undertaken
using different definitions of long-term outcome and different assumptions about the data.
Main Outcome Measure: Long-Term Disability.
Results: In these analyses, the same weighting-scheme was consistently selected by the recursive-partitioning algorithm.
This scheme reduced (down-weighted) the effectiveness of drug exposure as either disease duration or disability at
treatment-onset increased. Applying this scheme and using propensity-stratification to further mitigate bias, high-exposure
had a consistently better clinical outcome compared to low-exposure (Cox proportional hazard ratio=0.30–0.42; p,0.0001).
Conclusions: Early initiation and sustained use of interferon-beta-1b has a beneficial impact on long-term outcome in MS.
Our analysis strategy provides a methodological framework for bias-mitigation in the analysis of non-randomized clinical
data.
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Introduction
In general randomized controlled trials (RCTs) in many chronic
diseases such as multiple sclerosis (MS) only establish the short-
term efficacy of our current interventions [1]. Despite this, the
main medical, social, and economic impacts of these diseases are
typically caused by unremitting disability, which evolves slowly
over many years. However, establishing whether a therapy alters
long-term outcome of chronic disease is difficult because, in
general, RCT designs are ill-equipped for this purpose. It is not
realistic to continue a placebo arm after a drug has been
demonstrated to alter short-term outcomes that are believed to
be clinically relevant, especially after the therapy has been
approved. In this circumstance, many patients will not consent
to a prolonged placebo-exposure. Moreover, many clinicians are
already prepared to accept such short-term outcome information
as the basis for treatment decisions and, thus, would not
recommend their patient’s participation in a long-term placebo-
controlled trial. Inevitably, therefore, establishing long-term
efficacy for therapies of chronic diseases requires non-randomized
observational study-designs. The pivotal-trial of interferon-beta-1b
(IFNb-1b; BetaseronH), begun in 1988, was the first successful trial
of disease modifying therapy (DMT) in MS [2,3]. The patient-
cohort from this trial, which has now been followed out to 16
years, therefore, offers a unique opportunity to evaluate the
efficacy of long-term DMT use in MS.
Despite this potential value, however, any such assessment faces
several challenges. For example, when patients entered the RCT,
they did so at very different points along the continuum of the MS
disease course, with respect to both the disease-duration (i.e., the
time since their first clinical symptom) and its severity (i.e., their
disability status). If patient-characteristics such as these influence
either the likelihood of responding to treatment or the likelihood of
reaching a particular long-term outcome, baseline differences in
these factors could potentially confound any assessment of long-
term efficacy. Indeed, the RCT population had considerable
variability on these measures (Table 1) and there are several pieces
of evidence that suggest patients respond better to therapy earlier
in their disease course [4–12].
Following the trial, the decision to start, to continue, or to switch
therapy may also have been influenced by patient characteristics,
thereby, leading to an imbalance (bias) between treated and non-
treated patient-groups. Because such decisions are often based, in
part, on the perceived response to treatment, such outcome-
dependent variations in exposure (i.e., informed censoring) will
also confound assessment of long-term efficacy. Patients doing well
Table 1. Baseline and on-RCT clinical characteristics of the patients included (and those not included) in the detailed LTF
evaluation after 16 years*.
Patients in the
LTF population
Patients not in
LTF population p-value
{
Basleine Variables
Number of Patients 260** 112** –
% women 69% 71% 0.7125
Age at disease onset; (years) 27.3 (6.8) 27.7 (7.3) 0.5361
Age at start of RCT; (years) 35.4 (7.4) 35.8 (6.7) 0.5220
EDSS 2.9 (1.3) 2.9 (1.3) 0.8373
EDSS $3; (% of population) 138 (53%) 62 (55%) 0.7343
Disease Duration; (yrs) 8.0 (6.2) 8.1 (6.3) 0.9950
Baseline MSSS 4.3 (2.3) 4.4 (2.2) 0.7118
Baseline, MRI T2 BOD; (cm
2) 1.96 (2.0) 2.31 (2.4) 0.0699
Baseline, 3
rd ventricular width (mm) 4.86 (2.27) 5.19 (2.42) 0.1893
Annualized Relapse-rate (2 yrs prior to RCT) 1.68 (0.77) 1.67 (0.85) 0.5964
On-Study (RCT) Variables
Annualized Relapse-rate 1.2 (1.2) 1.6 (2) 0.0849
Change, EDSS (actual) 0.0 (1.3) 0.3 (1.6) 0.2415
Number of new T2 CAL 2.4 (3.3) 3.0 (4.0) 0.1613
Change, MRI T2 BOD (cm
2) 0.13 (0.6) 0.22 (1.0) 0.0729
Change, 3
rd ventricular width (mm) 0.62 (0.99) 0.63 (1.14) 0.7321
On IFNb-1b (250 mg) during RCT (%) 37% 25% 0.0178
*Means are listed without parenthesis. Standard deviations are shown in parentheses.
**7 deceased patients included in the LTF population; 28 deceased patients not included in LTF population.
{P-value derived from Fisher’s exact test for rates, z-score for percentages, and Wilcoxon’s rank-sum test for all others.
LTF=long-term follow-up; EDSS=Expanded Disability Status Scale score; MSSS=Multiple Sclerosis Severity Score; BOD=burden of disease; CAL=Combined Active
Lesions (New + Enlarging T2 Lesions).
doi:10.1371/journal.pone.0022444.t001
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switch. Similarly, physician or patient preference for certain
DMTs in certain circumstances may also lead to in an imbalance
in baseline or other characteristics between groups. Because of
these multiple potential sources of bias (Supplemental Material;
Appendix S1; Table S1), assessment of long-term efficacy, of
necessity, requires statistical methods that can mitigate these
effects.
Methods
Patients
Data were collected from patients who agreed to participate in
the 16-year long-term follow-up (LTF) of the IFNb-1b pivotal trial
[2,3]. The design of the LTF study is described elsewhere [13]
Briefly, patients from the original RCT [2,3] were asked to
participate in the LTF (see Protocol S1). Of the 372 patients in the
RCT, 328 (88.2%) were identified and provided some informa-
tion. Of these, 260 (70.0%; including the records from 7 who had
died) underwent a detailed assessment of their treatment history
and interim disease course (obtained through clinical evaluation
and medical record review), and a determination of their outcome
on a variety of long-term measures [13–16]. The extended
disability status scale (EDSS) scores at treatment-onset ranged
from 0 to 5.5, and treatment-exposure ranged from none (placebo-
treated patients who did not initiate therapy) to 16 years (patients
in the high-dose arm who continued therapy until the LTF
evaluation).
Comparison of baseline characteristics between those who did
and did not participate in the LTF indicated that both groups were
substantially similar by all measures (Table 1). During the RCT,
however, patients not participating in the LTF tended to have a
slightly more aggressive disease course compared to those who
participated (Table 1). Despite this tendency, a significantly greater
percentage of patients participating in the LTF were from the
group on IFNb-1b (250 mg) during the RCT compared to those
not participating (Table 1). Approval for the LTF study was
obtained from institutional review boards of all participating
centers. All patients gave written informed consent.
Therapy
During the RCT, patients received placebo (n=123), IFNb-1b
50 mg (n=125), or IFNb-1b 250 mg (n=124) subcutaneously
every-other-day for 104 weeks [2,3]. For our analysis, only the
high-dose (250 mg) group was considered to have received optimal
therapy at the time of randomization. This decision was made
both because low-dose IFNb-1b was less effective than the higher
dose [2,3] and because, on the basis of the evidence, the FDA
declined to approve its use in MS patients.
After completion of the RCT, all patients were offered the
opportunity of being treated with IFNb-1b (250 mg) until FDA
approval in 1993. No specific therapy was administered as part of
the LTF although, until the 1996 approval of IFNb-1a (AvonexH)
and glatiramer acetate (GA, CopaoxoneH), no other DMT was
available. Nevertheless, over the 16 years, many patients received
alternative DMTs [13]. However, IFNb-1b accounted for the vast
majority (.90%) of the overall time of DMT-exposure in the LTF.
Consequently, our principal analysis only considered IFNb-1b-
exposure.
Negative-outcome
‘‘Hard’’ negative-outcomes were defined as reaching
EDSS$6.0, wheelchair use, conversion to secondary progressive
(SP) MS, death, or the combined ‘‘any negative’’ outcome
consisting of one or more of these other outcomes. These hard
outcome measures are both clinically important and more reliable
than scores in the lower EDSS range. For our principal analysis,
the time to reaching EDSS$6 required confirmation $3 months
later. In addition to meeting this definition of confirmed
progression, however, the patient was also required still to be
EDSS$6 at all subsequent evaluations including at the LTF
evaluation. The purpose of this definition was to define the time at
which a person reached ‘‘unremitting’’ EDSS$6. SPMS was
defined as progressive disability evolving over $12 months and, in
the opinion of the investigator, not caused by relapses. Moreover,
EDSS must have increased by $1 point over the previous 2 years.
In addition, to be identified as SPMS, patients could not have
reverted to RRMS subsequent to meeting these criteria.
Besides weighted treatment-exposure, several other variables
potentially predictive of outcome were incorporated into the
analysis, including age, gender, treatment assignment during the
RCT, relapse-rate, EDSS, MS severity score (MSSS) [17],
baseline T2-weighted MRI lesion count and volume, 3
rd
ventricular width (a measure of atrophy), and neutralizing
antibody (NAb) status during the first 3 years of therapy
(Table 2). NAb-titers were measured in neutralizing-units per
milliliter (NU/ml). NAb-status was divided into 7 categories, each
of which could be combined with any (or several) of the other
categories. These categories were defined as: 1) always negative
(,20 NU/ml); 2) low titer (20–99 NU/ml); and 3) high-titer (one
or more assays with $100 NU/ml but not consecutive); and 4)
persistent high-titer (at least two consecutive titers $100 NU/ml
during the pivotal trial). Each of these subcategories was further
subdivided into titers that either reverted to NAb-negative status
(at some time during the RCT) or remained persistently positive
throughout the RCT.
Because complete MRI data was available for only about 75%
of the sample, the entire analysis was run twice. In the first, each of
the MRI variables (Table 1) were included. However, because
none of these variables were selected as predictors of outcome, for
the final analysis, these variables were omitted from consideration
so that the sample size could be as large as possible. Nevertheless,
importantly, the results of the analysis incorporating these MRI
variables were not substantively different from that excluding
them.
Cross-sectional cognitive data was obtained at the LTF
examination. However, because a time-to-event analysis with bias
mitigation was not possible for cognitive outcome, and because
baseline testing was available in only a few patients, the cognitive
data is presented elsewhere [15] and the impact of therapy on
cognitive outcome could not be determined [16].
Medication Possession Ratio (MPR) and Exposure
Weighting
Data analysis was undertaken as a step-wise process. The first
step (Supplemental Material; Appendix S1; Table S2; Step 1, A)
was to measure treatment-exposure, not as years of IFNb-1b
250 mg therapy, but to transform this variable into the so-called
‘‘medication possession ratio’’ or MPR [18,19]. The purpose of
this transformation was to compensate for the bias introduced by
physicians or patients making treatment decisions based on
perceived efficacy (i.e., outcome-dependent censoring of exposure)
[20]. Thus, the MPR was defined individually as:
MPR~(Actual-time of IFNb-1b exposure)=
(Total-time possible for IFNb-1b exposure)
Impact of IFNb-1b on Long-Term Outcome in MS
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the ‘‘raw’’ MPR the mitigating the bias of informative censoring
(Supplemental Material; Appendix S1; Table S1) is amply
demonstrated by comparison of an analysis using the actual
(unweighted) years of IFNb-1b-exposure to the same analysis
following ‘‘unweighted’’ MPR transformation (Figure 1). Using
‘‘unweighted’’ treatment exposure, the significance of the
treatment effect was (p,10
216). By contrast, using ‘‘unwieghted’’
MPR exposures, this apparent treatment effect is completely
mitigated, indicating that the initial observation was due to bias. It
was only after the possibility of exposure-weighting was intro-
duced, that treatment re-emerged as significant factor associated
with outcome (Figures 1 and 2).
Thus, these ‘‘raw’’ MPRs were weighted to account optimally
for the possibility that a patient’s response to therapy might be
different based on how long they had had their illness and how
Figure 1. The effect of MPR transformation on the bias introduced by informative-censoring of exposure (see text). In panel A are the
results of the RP analysis incorporating all of the baseline variables and the unweighted raw exposures (measured in years). In this analysis the
exposure variable (in years) dominates all other variables with a p-value of 10
216. However, in panel B, where the same analysis is conducted using
the unweighted-MPRs (in place of the unweighted ‘‘raw’’ exposures), the entire ‘‘spurious’’ treatment-effect disappears and the resulting tree is
identical to that found when all predictor variables (but not treatment) are included in the RP-analysis. In both Panels, the Kaplan-Meier survival
estimates are displayed below each of the identified subgroups (splits). X-axis is time in years. Y-axis is survival in % (1=100%).
doi:10.1371/journal.pone.0022444.g001
Table 2. Recursive Partitioning associating each predictor variable independently with ‘‘any negative-outcome’’ (p,0.20 to split).
Parameter explored Optimal split value p-value Interpretation
Age at 1
st symptom No split - No relationship found
Age at entry to RCT .37 years 0.11 Worse outcome with older age
Gender No split - No relationship found
Time from 1
st symptom to RCT start 2.35 years ,0.001 Worse outcome with longer duration
Treatment during RCT No split - No relationship found
Pre-RCT relapse-rate No split - No relationship found
Baseline EDSS Splits at .1,
.2,
.4
0.01
,0.001
,0.001
Worse outcome with higher baseline EDSS
Baseline MSSS .2.93 ,0.001 Worse outcome with higher baseline MSSS
Baseline MRI burden of disease (BOD) .2005.5 ,0.001 Worse outcome with higher baseline BOD
Baseline 3
rd ventricular width (atrophy) .3.947 0.002 Worse outcome with greater 3
rd ventricular width
NAbs; any titer and any persistence during RCT No split - No relationship found
doi:10.1371/journal.pone.0022444.t002
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Material; Appendix S1 for details).
Creating Treatment Groups
The best MPR weighting-scheme was taken to be the one
associated most significantly with a particular negative-outcome
using a recursive-partitioning (RP) algorithm. The RP method is a
two-step process [21,22]. The first step (Supplemental Material;
Appendix S1; Table S2; Step 1, B) identified which variable (in this
case, which weighted-exposure) was most significantly associated
with the particular negative-outcome [23]. The second step
(Supplemental Material; Appendix S1; Table S2; Step 2, B) used
recursive methods to identify the optimal split-point for the data
(Supplemental Material; Appendix S1; Figure S1) [24–26]. Statistical
significance was based on survival curves and associated log-rank
tests for the subgroups being compared (Supplemental Material;
Appendix S1; Figure S1) and the final significance adjusted (using a
Bonferroni correction) for the number of variables and weighting
schemes considered (Supplemental Material; Appendix S1).
The selected split-point for optimal-exposure (Supplemental
Material; Appendix S1; Figure S1) defined the exposure-groups
used in the final, integrated analysis (Supplemental Material;
Appendix S1; Table S2; Step 2, D). In theory, the RP algorithm
could have identified several weighted-MPR-exposure subgroups
although, in the LTF dataset, evidence was found for only two.
Although the split was based on weighted-MPR values, the
difference between the two groups in unweighted-MPRs was
notable. Thus, the median MPR in the high-exposure-group was
71% compared to a median of 0% in the low-exposure-group.
The RP algorithm was also applied to each of the predictor
variables individually (Table 2) to explore preliminarily the
relationships of these predictors to outcome. A ‘‘no-split’’
condition is defined for a given variable when that all of the
possible splits were non-significant (p.0.2). As an interim
verification model (Supplemental Material; Appendix S1; Table
S2; Step 2, C), we re-ran the RP algorithm including all predictor
variables together with all 161 weighted-MPR schemes (Supple-
mental Material; Appendix S1). This was done both to control the
overall experiment-wise Type I error and to verify the homoge-
neity of the selected weighting-scheme and treatment effect after
taking these other predictor variables into account. Theoretically,
although it did not occur, the RP algorithm could have selected (at
this step) a different weighting-scheme than that which was
selected previously (Supplemental Material; Appendix S1; Table
S2: Step 2, A). Such an occurrence might indicate heterogeneity in
response-behavior between different subgroups of patients. If so,
the entire analysis would need to be re-run considering each
subgroup separately.
We also examined the stability and robustness of the model
using multiple sensitivity analyses including different definitions of
‘‘hard’’ negative-outcome (i.e., EDSS$6, SPMS, wheelchair use,
death, either EDSS$6 or SPMS, and ‘‘any negative-outcome’’),
different assumptions about the underlying data, different
modeling approaches, and a variety of bootstrap methods
(Supplemental material; Appendix S1). Each of these demonstrat-
ed that the model was quite stable and robust (Figures 3,
Supplemental Material; Appendix S1; Figures S4 and S5; Table
S3).
Integrated Analysis
Final data analysis was done using a Cox proportional hazard
model to estimate the risk of a negative-outcome based on
exposure-group. To mitigate treatment-selection bias, a propensity
scoring approach was used [27–32]. Logistic regression was used
to estimate the likelihood that a patient would be in the ‘‘high’’ or
‘‘low’’ exposure-group using all available baseline characteristics
(Supplemental Material; Appendix S1; Table S2; Step 2, D). The
resulting likelihood estimates were then ranked to create bins in
which patients were equally likely to be in either exposure-group.
The Cox Regression model then used the propensity bin as a
stratification variable and strata pooled to estimate the overall
treatment-effect (Supplemental Material; Appendix S1; Table S2;
Step 3, A). Multiple sensitivity analyses were also undertaken to
assess the stability of the relationship between exposure-group and
negative-outcome and to assess the stability of the derived
relationships (Supplemental Material; Appendix S1) [33].
Statistical tests of significance
The significance of differences between subgroups for all RP
analyses was determined by the log-rank test and all reported p-
values, including the verification model with all variables
simultaneously considered (Supplemental Material; Appendix S1;
Table S2; Step 2, C), were adjusted for the multiple comparisons
Figure 2. Optimal split determined by the recursive partition-
ing algorithm considering all predictor variables (Table 2)
together with all possible weighted-MPR exposures to IFNb-1b.
Two highly significant split-levels were identified by the algorithm
based on EDSS at the start of therapy and weighted IFNb-1b exposure
during the LTF. The first split (as in the Supplemental Material;
Appendix S1; Figure S6) occurred at EDSS=2, whereas a second level
split occurred only for the EDSS.2 branch and was based on DMT
exposure. Importantly, the algorithm for this analysis selected precisely
the same weighting-scheme (bTN4SN2) that was selected in the
Supplemental Material (Appendix S1; Figure S7). Survival curves are
displayed below the identified subgroups and survival is best in the
EDSS#2 and the high-exposure groups. The split-point for DMT
exposure is slightly different than that identified in the Supplemental
Material (Appendix S1; Figure S7) because, in this instance, the split-
point was determined only from the subgroup of patients with an
EDSS.2. Note: the number (0.028) cannot be interpreted in time units
because it represents a mathematical transformation from the raw
exposure in years. In both Panels, the Kaplan-Meier survival estimates
are displayed below each of the identified subgroups (splits). X-axis is
time in years. Y-axis is survival in % (1=100%).
doi:10.1371/journal.pone.0022444.g002
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schemes) using a Bonferroni correction. If the treatment effect was
still significant after this analytic step (Supplemental Material;
Appendix S1; Table S2; Step 2, C), then the final propensity-
adjusted model (Supplemental Material; Appendix S1; Table S2;
Step 3, A) was generated via Cox regression and the p-value for
this final analysis was unadjusted for prior analysis steps.
Results
Each predictor variable was evaluated by the RP algorithm
independently and EDSS was the variable most strongly associated
with negative-outcome (Table 2). When EDSS was evaluated
alone, the RP algorithm identified four subgroups (Supplemental
Material; Appendix S1; Figure S6). When all predictor variables
were included (Table 2), the RP algorithm split only on EDSS and
the tree was identical, except that the EDSS=1 split (Figure S6;
Supplemental Material; Appendix S1) was eliminated by Bonfer-
roni adjustment (i.e., as in Figure 1-B). Baseline EDSS was also a
highly significant predictor of outcome using standard logistic-
regression analysis [14] In both analyses, the EDSS out-performed
the MSSS.
Survival curves for ‘‘high’’ and ‘‘low’’ exposure to IFNb-1b,
demonstrate a significant benefit to ‘‘high’’ exposure (Supplemen-
tal Material; Appendix S1; Figure S7). The results of our initial
validation (Supplemental Material; Appendix S1; Table S2; Step
2, C), when all predictor variables (Table 2) and all the weighted-
MPR exposure variables are included together in the same
analysis, indicate that only baseline EDSS and weighted
treatment-exposure remain as significant factors in determining
long-term outcome (Figure 2). Although Figure 2 might seem to
indicate that only patients with an EDSS.2.0 derived benefit
from therapy, there are two reasons to doubt this conclusion. First,
because of the weighting scheme selected, those patients who
entered the RCT with an EDSS.2.0, would have had a better
response if they were treated earlier. Second, this analysis
represents only an interim step to establish the independent
contribution of therapy to outcome. The principal, and intended
final, analysis was the propensity adjusted Cox model (see below).
Regardless of this nuance, however, it is of note that, despite
treatment having a very significant impact on outcome in this
analysis, the presence or absence of NAbs in the high-dose arm of
the RCT (at any titer level or any degree of persistence or in any
combination) did not mitigate this therapeutic effect. Also, when
all of the variables are considered simultaneously, the same
weighting-scheme is selected. As anticipated, there is a strong
correlation between treatment assignment during the RCT and
the weighted MPR. This is because the patients in the high-dosage
arm had a 100% MPR for the first 2–5 years whereas the patients
in the other arms had a 0% MPR for this same interval.
Nevertheless, despite this correlation, there was no discernable
association between treatment assignment and long-term outcome
(Table 2).
The results of our final analysis (Supplemental Material;
Appendix S1; Table S2; Step 3, A) showed very similar results.
Thus, the propensity-adjusted analysis using the optimal weight-
ing-scheme, found that the high-exposure-group much less likely
to experience ‘‘any negative-outcome’’ compared with the low-
exposure-group (HR=0.423; 95% CI; 0.275, 0.651; p,0.0001). A
similar result was found for every hard-outcome considered in this
trial (Figure 3) and was confirmed by each of the sensitivity
analyses performed (Supplemental Material; Appendix S1).
One of the underlying assumption of the Cox model is that of
proportionate hazard. We, therefore, considered the potential
impact of a violation of proportionate hazard and, indeed, this
assumption only holds until approximately 10 years after RCT
onset (Supplemental material; Appendix S1; Figure S8). After this
point point, the patients with EDSS.2 and more exposure begin
to fail at a greater rate than patients with EDSS.2 and less
exposure (Supplemental material; Appendix S1; Figure S8;). The
only way to satisfy the proportional hazards assumption is to
truncate the data at 10 years. However, censoring the data at this
point actually leads to a more extreme hazard ratio and a more
significant difference between the two groups. Such an outcome is
anticipated because any violation of the proportionate hazard
assumption should be biased toward the null hypothesis.
Discussion
The results of this study provide several pieces of important
evidence about the relationship between the use of IFNb-1b
therapy and long-term outcome in MS. First, therapy seemed to
have a consistent benefit on several measures of disability or
progression including EDSS, use of a wheel chair, or progression
to SPMS, and the combined measure of ‘‘any negative-outcome’’.
In this respect, our findings are similar to those reported previously
by Trojano and colleagues [31] which, after propensity adjust-
ment, demonstrated that 7 years of IFNb therapy reduced disease
progression as determined by the time to reach EDSS=4,
EDSS=6, and SPMS. Second, not only did every such analysis
(except death) show a statistically convincing and very similar
effect (Figure 3; Supplemental Material; Appendix S1; Table S3),
the magnitude of the benefit was also quite striking (Figures 2 and
3) with hazard ratios between 0.30 and 0.42. These two
observations provide evidence that the use of IFNb-1b results in
a significant and clinically meaningful impact on long-term
function in MS patients. Importantly, although there is a strong
Figure 3. Propensity adjusted Cox proportional hazard esti-
mates for the effect of treatment on each of the ‘‘hard’’
negative-outcomes examined in the study. The results for our
principal analysis (i.e., for ‘‘any negative-outcome’’) are shown on the far
left. For each of these outcomes, there is approximately a 60% to 70%
long-term benefit to therapy. Error bars indicate the 95% CI for each the
different outcomes.
doi:10.1371/journal.pone.0022444.g003
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the RCT and the weighted MPR, there was no discernable
association of this variable with outcome (Table 2). This indicates
that the observed benefit of therapy is not merely a reflection of
this early DMT experience. Importantly, also, our study provides
no information about the value of other DMTs because over 90%
of both the actual and the weighted-MPR exposure was from
treatment with IFNb-1b. This circumstance is due to two factors.
First, IFNb-1b was the only therapy available for the initial 6–8
years of the LTF. Second, the effect of any late DMT-exposure
was considerably down-weighted as a result of the selected
response curves (Supplemental Material; Appendix S1; Figure
S3). Therefore, our sensitivity-analysis of ‘‘any DMT-exposure’’,
in reality, merely recapitulates our analysis using IFNb-1b-
exposure alone.
Third, the weighting-schemes chosen by every one of the
different analyses were very consistent (Supplemental Material;
Appendix S1; Table S3), suggesting that this scheme is probably
accurate about when and how IFNb-1b is most effective. The
selected response curves (Supplemental Material; Appendix S1;
Figure S3) resulted heavy down-weighting with increasing EDSS
score and longer disease duration at therapy-onset. This suggests
that therapy is more effective when given early in the disease
course and is consistent with RCTs of both early MS (where the
effect size seems greater) and SPMS (where the effect size seems
less) compared to RCTs of relapsing-remitting MS [2,3,6–
8,11,34–45]. It is also consistent with the observation that the
on-therapy event-rates have fallen precipitously (even for the same
medications) in the last 5 years compared to the first 10 years of
the DMT era (Supplemental Material; Appendix S1; Figure S9).
There is little question that less advanced patients are now being
recruited into current randomized trials compared to earlier trials
and this marked change in event-rate suggests that patients treated
earlier in their disease course are responding much better to DMT
medication, just as one would expect from the selected response
curves shown in the Supplemental Material (Appendix S1; Figure
S3). In sum then, this analysis consistently supports the value of
early therapy. Moreover, this result seems unlikely to be due to
ascertainment bias (Supplemental Material; Appendix S1; Table
S1). Thus, despite a tendency to include, in the LTF, patients who
had somewhat less aggressive disease during the RCT (Table 1), a
greater percentage of the LTF patients were from the group on
IFNb-1b (250 mg) during the RCT compared to those not
participating (Table 1). Thus, the anticipated bias produced by
this imbalance should underestimate the benefit of treatment
because untreated patients (doing poorly during the RCT) seem
selectively less likely to have participated in the LTF.
This analysis also provides evidence for the utility of a
methodological framework that mitigates bias in the estimation
of long-term efficacy from non-randomized, observational, clinical
trials. This framework is outlined in the Supplemental Material
(Appendix S1; Table S2) and consists of several analytic steps,
which are also referenced throughout the description of our
analytic methods. The first step consists of data preparation and
the transformation of absolute exposures into raw-MPR exposures.
This step is critical because it converts the raw data, which are
heavily biased by informative-censoring of exposure due to a
patient’s perception of their own response, into data that are
corrected for this bias [20]. The second step consists of applying
weighting-schemes to allow flexibility in defining the exposure-
response relationship. This step is also critical because, by making
no adjustment to the raw-MPR data, the relationship between
exposure and outcome is forced to follow the bP0 (or eP0)
weighting-scheme (Supplemental Material; Appendix S1; Figure
S2). The third step is to use the RP algorithm to select the optimal
weighting-scheme, to define the exposure-groups, and to run
preliminary validation of the model. At the third step, the analysis
can fail and the process terminated. Thus, if no significant split-
point is found in the data during the selection of the optimal
weighting-scheme, this suggests that there is no relationship
between exposure and outcome. In this case, however, it is still
worthwhile repeating the analysis in the validation step (Supple-
mental Material; Appendix S1; Table S2; Step 2, C) to be sure that
a sub-group of patients is not responding. In this case, the analysis
should be repeated including only the identified sub-group. If
neither the initial RP nor the validation RP demonstrates a
significant treatment-effect, the analysis is terminated. Similarly, if
a significant split-point is initially found for treatment-exposure but
this relationship disappears when other predictor variables are
included in the RP algorithm, the analysis is terminated. If none of
these termination-events occurs, however, then logistic regression
is used to create propensity bins (based on the treatment groups
identified in step 3) and a propensity-stratified survival analysis
using a Cox proportional hazard model is undertaken to give an
estimate for the size of the treatment effect. This step is also critical
because propensity adjustment will mitigate any treatment-
selection bias, provided that the baseline variables (on which
treatment decisions were made) have been captured [27–32].
Indeed, using the method of propensity score adjustment, other
authors have also reported a beneficial impact of therapy on
outcome [31]. The last step is to perform multiple sensitivity-
analyses utilizing different definitions of negative-outcome,
different assumptions about the underlying data, and different
modeling approaches to ensure that the findings are both
consistent and robust. In summary, and, as exemplified by our
analysis of the LTF data from the IFNb-1b pivotal trial, utilization
of this analytic strategy can provide a useful method for the
minimization of bias in the analysis of non-randomized long-term
data.
Supporting Information
Figure S1 Derivation of split-points by the RP algorithm after
selection of the optimum baseline variable (Panel A) and the
optimum weighting-scheme (Panel B). In the case of the EDSS
there are only 10 possible split-points from which to choose
because the EDSS has only 10 possible split points from 0 to 5.5.
Panel B has many more data points because weighted MPR could
potentially be divided at many split-points. In both cases, however,
the algorithm picks the maximum value of the test statistic for
group-comparisons (in this case the log-rank test) to define the best
split-point. In Panel A the split could have been at either at
EDSS=2 or EDSS=3, as the test statistic was very similar at these
two points. In Panel B the choice is more clear-cut. Also note that
the actual of the ‘‘weighted’’ MPR is not meaningful because it
represents a mathematical transformation of the raw exposure
data in years into something that can’t be interpreted in unit of
time (see Figure S3).
(TIF)
Figure S2 The theoretical diffusion curves used for selecting
weighting-schemes by the recursive partitioning algorithm. Both
Bass diffusion curves (b) and exponential curves (e) were used (see
text). Curves that represent increasing effectiveness of therapy with
a increasing disease duration or EDSS score are called positive (P).
By contrast, those that represent decreasing therapeutic effective-
ness with increasing disease duration or EDSS are called negative
(N). From these 17 curves, it can be appreciated that this collection
(and selecting them in pairs) provides considerable flexibility to the
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selected. Pairs of curves that could be selected include cases in
which the MPR was decreased for one parameter (e.g., time since
first symptom) and increased for the other (e.g., EDSS at therapy
initiation) in addition to cases in which the MPR was increased (or
decreased) for both parameters.
(TIF)
Figure S3 Calculation of the weighted-MPR for an individual
beginning therapy after 2 years of disease and at an EDSS of 3.0.
Panel A shows the selected (bTN4SN2) weighting scheme (i.e. the
bN4 and bN2 curves – Figure S2). On the x-axis the term
(EDSS?2) represents twice the EDSS score in order to simplify the
graph. The designation (T) means that the time (disease duration)
criteria is following bN4 curve whereas the designation (S) means
that the severity (EDSS) criteria is following the bN2 curve
(Figure 3). The table below the graph shows the calculation for the
average weight. Panel B shows a two-dimensional graph of the
same weighting-scheme as in Panel A for any combination of
EDSS (Severity) and Duration (Time) at the onset of therapy, with
100% weighting (in dark blue) at the origin transitioning to 0% at
the upper right corner (in red). The black square indicates this
particular patient’s location on this graph. Panel C shows how this
weighting-scheme affects the MPR given this person’s individual
treatment history. The times that different outcomes were reached
are indicated on the top line. A color-code for outcomes and
treatments is at the bottom. Just prior to reaching EDSS=6, this
patient was switched to IFNb-1a (AvonexH). Because the Avonex is
started within 3 months of discontinuing to IFNb-1b (BetaseronH),
the weighting for the two drugs is the same. Because the other
therapy was started more than 3 months after discontinuing to
IFNb-1a (AvonexH) and because it was started at such a long
disease duration (,10 yrs + the disease duration at the RCT start),
it has been down-weighted to almost zero.
(TIF)
Figure S4 Percentage of the time that different weighting
schemes were selected in the 2,000 samples selected using
bootstrap methods (see text for details). The ‘‘optimal’’ weighting
scheme (bTN4SN2) was chosen in 52% of the time. However, the
next most commonly selected weighting schemes (bTN4SN3,
eTN4SN3, eTN4SN4, and bTN1SN3) are similar to the
bTN4SN2 scheme (Figures S2 and S3), with each markedly
down-weighting the value of exposure both for an increased
disease duration and for a greater EDSS at the start of therapy (see
Figures S2 and S3). The solid black line shows the cumulative
probability for the selected weighting schemes, with the first 5
schemes being selected more than 90% of the time. See Figure
legends S2 and S3 for the definitions of b, e, P, N, T, and S.
(TIF)
Figure S5 Various tests of the stability of the Model. All panels
A–D follow a similar structure. The leftmost, filled, black circle
represents the original estimate observed using all 260 observa-
tions exactly once and the 5-bin propensity score adjustment
method. For instance, the relative risk of any negative event was
estimated to be 0.44 for the ‘‘more’’ treatment group compared to
the low treatment group (p,0.001). After the ‘‘Original’’ estimate
3 sets of 3 other estimates are provided. The estimates are grouped
first based on the weighting scheme that was selected. Immediately
next to the ‘‘Original’’ estimate is the estimate that is observed
only including the bootstrap samples where weighting scheme
bTN4SN2 was selected, followed by bTN4SN3 and eTN4SN3
(the 2
nd and 3
rd ranked weighting schemes). Within each weighting
scheme block, three modeling strategies are tested: (1) 5 bin
propensity score adjustment, (2) stepwise selection with all terms
included as covariates in the Cox Model, and (3) no adjustment
(e.g., treatment effect is the only term entered into the model). A
horizontal line extends from the ‘‘Original’’ point estimate for easy
comparison. Vertical lines from each point estimate provide 95%
confidence intervals based on the bootstrap sample and employing
the empirical percentile confidence interval approach. In Panel A
the effect size for treatment in the ‘‘high-exposure’ group is shown.
The horizontal dotted lines represent the 95% CI for the original
analysis (including all of the 260 original observations). Panel B
shows the levels of statistical significance for each analysis method
and weighting scheme. The lower two panels (C and D) shows the
predictive accuracy of the model (i,e, the area under the Receiver-
Operator curve or the C-Index) for the bootstrap sample (’’In
Bag’’) and for the observations not in the bootstrap sample (‘‘Out
of Bag’’ or OoB).
(TIF)
Figure S6 Optimal split determined by the RP algorithm
considering only EDSS at the start of therapy. Two highly
significant split-levels were identified by the algorithm based on
EDSS at the trial entry. The first split occurred at EDSS=2 and
subsequent splits were found for both branches. Survival curves
are displayed below each of the identified subgroups with survival
markedly deteriorating with higher EDSS scores at trial entry.
After including all predictor variables (except treatment) into the
model, the secondary split-point at EDSS=1 becomes non-
significant after controlling for Type 1 error with a Bonferroni
adjustment. Below the splits, the survival curves are plotted. X-axis
is time in years. Y-axis is survival in % (1=100%).
(TIF)
Figure S7 Optimal split determined by the recursive partition-
ing algorithm considering only weighted-MPR exposure to IFNb-
1b. In this analysis, the RP algorithm was presented with all
weighting-schemes (161) and selected the bTN4SN2 weighting-
scheme as the one most closely associated with a negative-
outcome. This is the one used in this analysis and the survival
curves for the optimally split data are shown. The left-hand panel
shows survival in the low-exposure group whereas the right-hand
panel shows much better survival in the high-exposure group.
Note: the number (0.034) cannot be interpreted in time units
because it represents a mathematical transformation from the raw
exposure in years. Below the splits, the survival curves are plotted.
X-axis is time in years. Y-axis is survival in % (1=100%).
(TIF)
Figure S8 Superimposed survival curves for the same three
groups presented previously in Figure 2 (Main paper). As can be
appreciated from the Figure, the proportional hazard assumption
only holds out to approximately 10 years. After that point, the
patients with EDSS.2 and more exposure (blue line) begin to fail
at a greater rate than patients with EDSS.2 and less exposure
(red line). The only way to satisfy the proportional hazards
assumption is to truncate the data at 10 years. Censoring the data
at this point, however, actually leads to a more extreme hazard
ratio and a more significant difference between the two groups.
Such an outcome is anticipated because any violation of the
proportionate hazard assumption should be biased toward the null
hypothesis.
(TIF)
Figure S9 The on-therapy event-rate (annualized attack-rate) in
clinical trials since the completion of the original IFNb-1b
(BetaseronH) trial
2, 3 in 1992. Other trials include COP-1 (GA,
CopaxoneH)
33; MSCRG (IFNb-1a, AvonexH)
34; PRISMS (IFNb-
1a, RebifH)
35; OWIMS (IFNb-1a, RebifH)
36; EVIDENCE (RebifH
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37; INCOMIN (BetaseronH vs. AvonexH)
38; AFFIRM
(natalizumab, TysabriH)
39; SENTINEL (AvonexH vs. AvonexH
plus TysabriH)
34; CamMS (alemtuzamab, CampathH vs. Re-
bifH)
41; REGARD (RebifH vs. CopaxoneH)
9; BEYOND (Betaser-
onH 500 mg vs. BetaseronH 250 mg vs. CopaxoneH)
10; CLARITY
(Cladribine)
43; TRANSFORMS (Fingolimod)
44; and FREE-
DOMS (Fingolomid).
45 These event-rates, even for the same
study medications (BetaseronH, RebifH, and CopaxoneH), have
fallen precipitously in the past 5 years, at least in part, because
current trials tend to recruit patients with more mild disease (i.e.,
more patients with short disease courses and more patients with
lower EDSS scores) compared to trials undertaken when no
proven DMTs were available.
(TIF)
Table S1 Sources of Bias and Corrective Strategies.
(DOC)
Table S2 Strategy for bias-minimization in the analysis of non-
randomized observational data.
(DOC)
Table S3 Sensitivity analyses using alternative definitions of
outcome and exposure.
(DOC)
Protocol S1
(PDF)
Appendix S1
(DOC)
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